Astragaloside IV alleviates M3 subtype of the muscarinic acetylcholine receptor blockade-induced myocardial apoptosis through p53/Akt signaling pathway in myocardial ischemia model.

Abstract

Astragaloside IV (AS-IV), as the primary active component and nutritional supplement of Astragali Radix, has a definite cardioprotective effect. However, it is unknown whether AS-IV could prevent myocardial ischemia by triggering M3 subtype of muscarinic acetylcholine receptor (M3 receptor) and control cardiomyocytes apoptosis via p53/Akt. The objective of this research is to create an in vivo model of myocardial ischemia (MI) and use morphological, bioinformatics, and molecular biology techniques to clarify how AS-IV controls MI and apoptosis via the M3 receptor and p53/Akt pathways. The findings implied that AS-IV could mitigate the MI damage and exacerbated apoptosis of cardiomyocytes brought onby M3 receptor inhibitors 4-DAMP in vivo. Furthermore, AS-IV may have a protective effect on MI by directly interacting with M3 receptor. In terms of mechanism, AS-IV's anti-apoptotic effect could be associated with the regulation of the p53/Akt signalling pathway. Altogether, our findings suggest that AS-IV may reduce MI and exert myocardial protective effects via influencing on the M3 receptor and p53/Akt signalling pathways. This study offers a theoretical foundation for investigating possible protective targets of AS-IV and clarifying novel roles and mechanisms of AS-IV.